TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
INCLUSION CRITERIA:~* All patients receiving a T cell depleted BMT from a mismatched family member or unrelated donor will be eligible for this protocol. In addition, patients receiving a matched sibling transplant or T replete transplant may be eligible if they are at high risk of developing EBV LPD because of their underlying disease (e.g Wiskott-Aldrich or Ataxia Telangiectasia) or have a past history of EBVLPD or other EBV associated malignancy.~* O2 saturation \> 90% on room air~EXCLUSION CRITERIA:~- Exclusion criteria for BMT will be as detailed in the relevant protocol.~Exclusion criteria at time of administration CTLs:~* Patients with GVHD of Grade II or greater.~* Patients with severe renal disease (i.e., creatinine clearance less than half normal for age).~* Patients with severe hepatic disease (bilirubin greater than twice normal, or SGOT greater than 3 x normal).~* Patients with a severe intercurrent infection.~* Patients with a life expectancy \<6 weeks

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- EBV specific T cells (Type: EXPERIMENTAL): EBV specific T cells

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Effect of Chlorogenic Acid on Patients With Impaired Glucose Tolerance

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* BMI: 30.0-34.99 kg / m2.~* Diagnosis of IGT (OGTT Values between 140mg / dl and 199mg / dl.~* Written informed consent.~* Body weight stable over the last 3 months.~* Women in follicular phase of the menstrual cycle (days 3 to 8 of the cycle) at the time of laboratory tests.~* Women who are not contemplated get pregnant within the next 6 months.~Exclusion Criteria:~* Women pregnant or breastfeeding.~* Physical or mental disability that makes it impossible to perform the intervention.~* Diagnosis of Hypertension or heart failure.~* Smokers.~* Untreated thyroid disease.~* Consumption of oral agents or other medications or supplements with proven properties that modify the behavior of glucose and lipids (oral hypoglycemic agents, insulin, lipid-lowering).~* Diagnosis of liver disease or elevation twice of the upper normal value of liver enzymes.~* Diagnosis of renal disease or creatinine \> 1.5 mg / dl.~* Diagnosis of Type 2 Diabetes Mellitus (T2DM) Fasting glucose ≥ 126 mg / dL and/or OGTT ≥ 200 mg / dL and/or A1C ≥ 6.5%.~* Total Cholesterol ≥ 280 mg/dL.~* Triglycerids ≥ 300 mg/dL.~* Known allergy to calcined magnesia or Chorogenic acid.

- Gender: ALL
- Minimum Age: 30 Years
- Maximum Age: 60 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): 1200 mg dose per day, three capsules of 400 mg, times daily 1/ 2 hour before meals during 90 days.
- Chlorogenic acid (Type: EXPERIMENTAL): 1200 mg dose per day, three capsules of 400 mg, times daily 1/ 2 hour before meals during 90 days.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Adjuvant Gemcitabine Versus 5-FU/Leucovorin Based on hENT1 Immunostaining

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with curatively resected pancreatic cancer~* Age between 18 and 75~* Eastern Cooperative Oncology Group performance score 0 or 1~* Patients with compliance~* Patients with informed consent~Exclusion Criteria:~* Patients refuse to enroll this study~* Patients with concomitant chemoradiation therapy~* Previous chemotherapy~* Pregnant or preparing a pregnancy~* Uncontrolled infection, diabetes, hypertension, ischemic heart disease, myocardial infarction within 6 months~* Enrolled another clinical trial within 30 days~* Patients will be expected to be risk because of enrollment~* Patients without informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- 5-FU group (Type: ACTIVE_COMPARATOR): Grades of hENT1 immunostaining are 0 or 1.
- Gemcitabine group (Type: ACTIVE_COMPARATOR): Grade of hENT1 immunostaining is 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Transcricoid Injection vs. Spray as You go Method for Local Anaesthesia During EBUS-TBNA

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Indication for EBUS TBNA~* Age \> 18 years~Exclusion Criteria:~* Refusal of consent~* Known documented hypersensitivity to lignocaine~* Procedure performed under general anaesthesia~* Pregnancy~* Hypoxemia (oxygen saturation \[by pulse oximetry\] \< 92% with Fio2 of ≥ 0.3~* Bronchoscopy done through endotracheal or tracheostomy tube~* Midline neck mass or thyroid enlargement making the identification of~* cricothyroid membrane difficult'~* Patients with central airway obstruction~* Patients with active ongoing hemoptysis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Transcricoid (Type: ACTIVE_COMPARATOR): Lignocaine delivery using transcricoid injection
- Spray as You go (Type: ACTIVE_COMPARATOR): Lignocaine delivery using spray as you go method

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy of Transverses Abdominis -Plane Block With Bupivacaine Versus Bupivacaine With Morphine Postoperatively

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 60 ASA I-II cancer patients with age range (18-60) years,~* weight (50- 85) kg~Exclusion Criteria:~* with patients with known drug allergy to study drugs~* with significant cardiac, respiratory, renal or hepatic disease~* with coagulation disorders~* those with psychiatric illnesses that would interfere with perception and assessment of pain.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 60 Years
- Healthy Volunteers: t

Study Arms:
- TAP with bupivicaine (Type: PLACEBO_COMPARATOR): 30 patients receive ultrasound guided transversus abdominis-plane block (TAP) with local anesthetic 20 ml of bupivacaine 0.5 % diluted in 20 ml saline (total volume 40 ml) in two divided doses i.e. 20 ml is administered on each side of the abdominal wall.
- TAP with bupivicaine with morphine (Type: ACTIVE_COMPARATOR): 30 patients receive ultrasound guided transversus abdominis-plane block (TAP) with local anesthetic 20 ml of bupivacaine 0.5% + 10 mg morphine diluted in 20 ml saline (total volume 40 ml) in two divided doses i.e. 20 ml is administered on each side of the abdominal wall.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: 18F-AV-1451 Autopsy Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Have a projected life expectancy of ≤ 6 months~* Can tolerate a 20 minute PET scan~* Give informed consent or have a legally authorized representative to consent for study procedures and brain donation consistent with the legal requirements of the State in which they die~Exclusion Criteria:~* Aggressively being treated with life sustaining measures~* Known to have a structural brain lesion that would interfere either with PET imaging or pathological assessment~* Clinically significant infectious disease~* Currently receiving any investigational medications except with permission from the study sponsor~* Participated in an experimental study with an amyloid or tau targeting agent~* Suspected encephalopathy due to alcoholism or end-stage liver disease~* Females of childbearing potential~* History of risk factors for Torsades de Pointes or are currently taking medication known to cause QT prolongation

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Flortaucipir PET Scan (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Real-life Effectiveness of Vortioxetine in Depression

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* The patient is ≥18 years~* The patient is an outpatient, treated in a GP or psychiatric outpatient practice~* The patient has a diagnosis of major depressive episode according to local diagnostic criteria~* The patient has been prescribed vortioxetine according to the local Summary of Product Characteristics (SmPC)~Exclusion Criteria:~* The patient is unable to read and understand the information sheet and informed consent form or the Patient Reported Outcomes (PRO)~* The patient is concurrently participating in a clinical trial~* The patient has a diagnosis of schizophrenia or other psychotic disorder according to local diagnostic criteria~* The patient has a diagnosis of bipolar disorder according to local diagnostic criteria~* The patient has a substance use disorders other than tobacco use disorder~* The patient has dementia or other neurodegenerative disease significantly impacting cognitive functioning~* The patient has a mood disorder due to a general medical condition or substances~* The patient is pregnant, ≤6 months post-partum or breastfeeding~* The patient is at significant risk of suicide in the investigator's opinion or the patient has attempted suicide within the last six months~* The patient is a member of the study personnel or of their immediate families, or is a subordinate (or immediate family member of a subordinate) to any of the study personnel

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients initiating vortioxetine treatment (Type: None): Patients with major depressive disorder initiating treatment with vortioxetine

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Gene Therapy Study in Severe Haemophilia A Patients (270-201)

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Males 18 years or older with established severe Haemophilia A (endogenous FVIII level ≤1 IU/dL) as evidenced by their medical history.~2. Treated/exposed to FVIII concentrates or cryoprecipitate for a minimum of 150 exposure days (EDs)~3. Greater than or equal to 12 bleeding episodes for patients on on-demand FVIII replacement therapy over the previous 12 months. Does not apply to patients on prophylaxis~4. No history of inhibitor, and results from a modified Nijmegen Bethesda assay of less than 0.6 Bethesda Units (BU) 2 consecutive occasions at least one week apart within the past 12 months~5. Sexually active patients must be willing to use an acceptable method of contraception.~Exclusion Criteria:~1. Detectable pre-existing immunity to the AAV5 capsid as measured by AAV5 transduction inhibition or AAV5 total antibodies~2. Any evidence of immunosuppressive disorder or active chronic infection including hepatis B, hepatitis C, HIV~3. Significant liver dysfunction as defined by abnormal elevation ofliver function tests, or for patients who have undergone liver imaging or biopsy and found to have evidence of grade 3 or higher fibrosis~4. Evidence of any bleeding disorder not related to haemophilia A~5. 12. Treatment with any investigational product within 30 days prior to the end of the screening period, or any previous exposure to any gene transfer therapy~6. Any disease or condition that per the physician's discretion would prevent the patient from fully complying with the requirements of the study including possible corticosteroid treatment outlined in the protocol. The physician may exclude patients unwilling or unable to agree on not using alcohol for the 16-week period following the viral infusion.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- valoctocogene roxaparvovec (Type: EXPERIMENTAL): Single administration of valoctocogene roxaparvovec at escalating doses.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Chronic Asthma Study in 2- to 5-Year-Old Patients (MK0476-072 )

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patient has history of physician diagnosed asthma~* Patient is in otherwise good stable health~* Patient is able to chew a tablet~Exclusion Criteria:~* Patient is hospitalized~* Patient and/or parent of guardian intends to move or vacation away from home during the course of the study~* Patient had any major surgical procedure within 4 weeks before the study~* Patient had active sinus disease within 3 weeks before the study~* Patient had required intubation for asthma in the past~* Patient required a visit to the emergency room due to an asthma exacerbation, or has been hospitalized for asthma with in 1 month prior to the study~* Patient had used inhaled, nebulized, intramuscular, or intravenous steroids with in 1 month before study

- Gender: ALL
- Minimum Age: 2 Years
- Maximum Age: 5 Years
- Healthy Volunteers: f

Study Arms:
- 1 (Type: EXPERIMENTAL): Montelukast
- 2 (Type: PLACEBO_COMPARATOR): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dry Eye Study With Cosopt® Over 8 Weeks in Patients With Open-Angle Glaucoma or Ocular Hypertension (0507A-152)(COMPLETED)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Adult patient with newly diagnosed and untreated for open-angle glaucoma or ocular hypertension with an Intra-ocular Pressure (IOP) of \> 27 mm Hg (in at least one eye) and a baseline GSS SYMP-6 total score of 75 or less~* Patient is male or a female who is highly unlikely to conceive~* Patient has been recently diagnosed and is presently untreated for open-angle glaucoma or ocular hypertension with an IOP of at least 27 mm Hg in at least one eye (patient's worse eye)~* Patient already diagnosed with open-angle glaucoma or ocular hypertension and untreated for at least 30 days are eligible for the study if they have an IOP of 27 mm Hg or more in at least one eye~Exclusion Criteria:~* A history of any illness that, in the opinion of the investigator, might confound the results of the study or pose additional risk by administering preservative free dorzolamide-timolol (preservative-free Cosopt®)~* The presence of any fundus pathology likely to change during the study or to influence IOP (background of diabetic retinopathy is permitted)~* Any contraindication to the use of preservative-free Cosopt® including:~* bronchospasm, including bronchial asthma or a history of bronchial asthma or chronic obstructive pulmonary disease, sinus bradycardia, second or third degree AV block, cardiac failure (grade III and IV), cardiogenic shock, severe renal impairment (serum creatinine \> 150 umol/L or creatinine clearance \< 30 ml/min)~* Patient on:~* carbonic anhydrase inhibitor, concomitant systemic or dermatological medication known to affect the IOP, e.g. clonidine, corticosteroids, oral beta-blocking agents. patient on a non-glaucoma medication that contains a preservative agent, i.e. benzalkonium chloride, benzododecinium bromide or stabilized oxychloro complex~* Patient with hypersensitivity to any component of preservative free dorzolamide-timolol (preservative-free Cosopt®)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Aerosol Cyclosporine for Prevention of Lung Rejection

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: None

Eligibility Criteria:
No eligibility criteria

- Gender: ALL
- Minimum Age: None
- Maximum Age: 100 Years
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Belatacept Evaluation of Nephroprotection and Efficacy as First-line Immunosuppression (BENEFIT)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* The subject is a recipient of a living donor or deceased donor kidney transplant.~* Male or Female, 18 or older~Exclusion Criteria:~* First time recipient, PRA \>- 50% or for retransplantation PRA \>- 30%.~* If retransplantation, previous graft loss cannot be due to acute rejection.~* Positive cross match.~* Subject receiving extended criteria donor (ECD) organ~* For Long-term extension study-Subjects who have completed three years of study treatment (through Week 156)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Cyclosporine (CsA) (Type: ACTIVE_COMPARATOR): None
- Belatacept LI (less intensive) (Type: EXPERIMENTAL): None
- Belatacept MI (more intensive) (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Long-term Study of Teduglutide in Pediatric Subjects With Short Bowel Syndrome Who Completed the TED-C13-003 Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Subject provides written informed consent (subject, parent or legal guardian and, as appropriate, subject informed assent) to participate in the study before completing any study-related procedures.~2. Subject completed the TED-C13-003 study (including subjects in the standard of care treatment arm).~3. Subject understands and is willing and able to fully adhere to study requirements as defined in this protocol.~Exclusion Criteria:~There are no exclusion criteria for this study.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Standard of Care (SOC) Treatment +/- Teduglutide (Type: EXPERIMENTAL): TED 0.05mg/kg subcutaneous injections once daily as needed in addition to SOC treatment

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete